Tags

Type your tag names separated by a space and hit enter

Sclerosing cholangitis.
Curr Opin Gastroenterol 2006; 22(3):288-93CO

Abstract

PURPOSE OF REVIEW

Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of the biliary tree complicated by cirrhosis and cholangiocarcinoma. It is immune mediated although the precise etiology remains unknown.

RECENT FINDINGS

Research into etiopathogenesis, epidemiology, the relationship with inflammatory bowel disease, diagnosis of cholangiocarcinoma, medical therapy, and the outcome of liver transplantation are discussed.

SUMMARY

It is likely that a number of patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct clinicopathological features including steroid responsiveness. Primary sclerosing cholangitis-inflammatory bowel disease probably represents a distinct inflammatory bowel disease phenotype, which has implications for colonoscopic surveillance of these patients. CA19-9 plays no surveillance role for the early detection of cholangiocarcinoma. The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, despite a range of potentially valuable actions on the cholestatic liver, has not yet been proved to make a substantial impression on the course of the disease. Orthotopic liver transplantation remains the only established long-term treatment for primary sclerosing cholangitis.

Authors+Show Affiliations

Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16550044

Citation

MacFaul, George R., and Roger W. Chapman. "Sclerosing Cholangitis." Current Opinion in Gastroenterology, vol. 22, no. 3, 2006, pp. 288-93.
MacFaul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol. 2006;22(3):288-93.
MacFaul, G. R., & Chapman, R. W. (2006). Sclerosing cholangitis. Current Opinion in Gastroenterology, 22(3), pp. 288-93.
MacFaul GR, Chapman RW. Sclerosing Cholangitis. Curr Opin Gastroenterol. 2006;22(3):288-93. PubMed PMID: 16550044.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sclerosing cholangitis. AU - MacFaul,George R, AU - Chapman,Roger W, PY - 2006/3/22/pubmed PY - 2006/9/13/medline PY - 2006/3/22/entrez SP - 288 EP - 93 JF - Current opinion in gastroenterology JO - Curr. Opin. Gastroenterol. VL - 22 IS - 3 N2 - PURPOSE OF REVIEW: Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of the biliary tree complicated by cirrhosis and cholangiocarcinoma. It is immune mediated although the precise etiology remains unknown. RECENT FINDINGS: Research into etiopathogenesis, epidemiology, the relationship with inflammatory bowel disease, diagnosis of cholangiocarcinoma, medical therapy, and the outcome of liver transplantation are discussed. SUMMARY: It is likely that a number of patients previously diagnosed with primary sclerosing cholangitis have autoimmune pancreatitis in association with primary sclerosing cholangitis, a syndrome with distinct clinicopathological features including steroid responsiveness. Primary sclerosing cholangitis-inflammatory bowel disease probably represents a distinct inflammatory bowel disease phenotype, which has implications for colonoscopic surveillance of these patients. CA19-9 plays no surveillance role for the early detection of cholangiocarcinoma. The best-studied drug in primary sclerosing cholangitis is ursodeoxycholic acid, which, despite a range of potentially valuable actions on the cholestatic liver, has not yet been proved to make a substantial impression on the course of the disease. Orthotopic liver transplantation remains the only established long-term treatment for primary sclerosing cholangitis. SN - 0267-1379 UR - https://www.unboundmedicine.com/medline/citation/16550044/Sclerosing_cholangitis_ L2 - http://Insights.ovid.com/pubmed?pmid=16550044 DB - PRIME DP - Unbound Medicine ER -